Target's General Information
Target ID T73097
Target Name GMCSFR-alpha (CSF2RA)
Synonyms GMR; GM-CSFR; GM-CSF-R-alpha; CSF2RA; CDw116; CD116 antigen
Target Type Successful
Gene Name CSF2RA
Biochemical Class Type I cytokine receptor family
UniProt ID CSF2R_HUMAN
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Acute myelocytic leukemia
Example drug Leukemia cancer vaccine Phase 2 [1], [2], [3]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.49
Z-score: -0.88
P-value: 1.10E-05
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Glioma
Example drug AFTVac Phase 2 [2], [3], [4]
Tissue Brainstem tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.13
Z-score: -0.28
P-value: 7.80E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Glioma
Example drug AFTVac Phase 2 [2], [3], [4]
Tissue White matter
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.44
Z-score: 0.38
P-value: 1.96E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Myeloma
Example drug Myeloma cancer vaccine Phase 2 [1], [2], [3]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.14
Z-score: 1.25
P-value: 3.76E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Rectal cancer
Example drug Colorectal cancer vaccine Phase 2 [2], [3], [5]
Tissue Rectal colon tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.43
Z-score: -2.15
P-value: 4.48E-03
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: -0.25
Z-score: -1.13
P-value: 1.01E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Rheumatoid arthritis
Example drug Mavrilimumab Phase 2 [2], [3], [6], [7]
Tissue Synovial tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.16
Z-score: 0.53
P-value: 8.42E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Multiple sclerosis
Example drug MOR-103 Phase 1/2 [8], [2], [3]
Tissue Spinal cord
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 0.06
Z-score: 0.24
P-value: 1.58E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
REF 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 3 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
REF 4 Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
REF 5 Clinical pipeline report, company report or official report of Aduro BioTech.
REF 6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7785).
REF 7 Clinical pipeline report, company report or official report of MedImmune (2011).
REF 8 ClinicalTrials.gov (NCT01023256) Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.